Acute Coronary Syndrome – Landscape & Forecast – Disease Landscape & Forecast (G7)

Acute coronary syndrome (ACS) is a leading cause of morbidity and mortality in developed countries. Despite aggressive management of atherothrombotic risk factors through LDL-C lowering, blood-pressure control, and antithrombotic therapy, post-ACS patients face a lifelong risk of recurrent ischemic events. This persistent residual risk is driving the expansion of the long-term ACS secondary prevention market, with innovation increasingly focused on more intensive lipid management and biomarker-defined treatment of residual risk. Market growth will be driven primarily by continued intensification beyond statins and ezetimibe, including broader use of PCSK9 inhibitors, and selective use of additional oral LDL-C-lowering agents such as bempedoic acid and obicetrapib. The market will also expand through novel mechanisms that address residual risk beyond traditional factors. Lp(a) inhibitors and ziltivekimab will create new add-on opportunities by targeting elevated Lp(a) and residual inflammatory risk, respectively. Antithrombotics are not covered in this report.

Questions answered

• What factors will drive and constrain the growth of the post-ACS market?
• How will Lp(a) inhibitors be clinically positioned, and what is their commercial opportunity?
• Will emerging PCSK9 inhibitors expand overall class use, or mainly drive a shift away from evolocumab and alirocumab?
• How does bempedoic acid’s positioning differ across the G7 markets?
• How do cardiologists perceive obicetrapib’s clinical value and differentiation as an oral CETP inhibitor in a crowded non-statin LDL-C-lowering landscape?
• How do cardiologists expect ziltivekimab to be integrated into post-ACS care, and which patients will be selected for treatment?

Geography

United States, EU5, Japan

Primary research

• Country-specific interviews with thought-leading cardiologists
• Survey data collected for this and other Clarivate research

Epidemiology

Lifetime diagnosed prevalent cases of ACS by country

Forecast

10-year, annualized, drug-level sales and patient share of key ACS secondary prevention therapies through 2035, segmented by brands / generics

Drug treatments

Coverage of key current and late-phase emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.